Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05612789 · ClinicalTrials.gov registry record · NA

Improve Outcomes for Older Allogeneic Transplant Recipients

A NA study of Allogeneic Transplantation, sponsored by Abramson Cancer Center at Penn Medicine.

Recruiting
Registry status
NA
Development phase
72
Enrollment target
1
Study location

NCT05612789 is a NA study of Allogeneic Transplantation that is actively recruiting participants, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 72 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05612789, a NA study of Allogeneic Transplantation, is actively recruiting participants, sponsored by Abramson Cancer Center at Penn Medicine.

RECRUITING
Registry status
NA
Development phase
72 participants
Enrollment target
1
Study location

Study Summary

This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as those participating in the exercise intervention.

Conditions Studied

Interventions

  • BEHAVIORAL Exercise Program (Cohort A Prehab)
  • BEHAVIORAL Exercise Program (Cohort B Rehab)

Study Locations (1)

Pennsylvania

  • Penn Medicine - Philadelphia

Trial Details

FieldValue
Enrollment Target 72 participants
Start Date 2023-02-15
Est. Completion 2031-06-01
Phase NA

What the Registry Record Tells You About NCT05612789

The ClinicalTrials.gov registry entry for NCT05612789 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Allogeneic Transplantation appearing as the primary indexed condition, and to 2 interventions - of which Exercise Program (Cohort A Prehab) is the first listed.

NCT05612789 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT05612789 about?

NCT05612789 is a clinical study titled "Improve Outcomes for Older Allogeneic Transplant Recipients". This is an interventional pilot study to determine whether implementation of a supervised exercise program can improve outcomes in subjects undergoing allogeneic HCT. The primary objective is to determine feasibility. Up to 60-72 evaluable subjects will be enrolled. Evaluable subjects are defined as...

What is the current status of trial NCT05612789?

This trial is currently recruiting. It is a NA study. The enrollment target is 72 participants. The study started on 2023-02-15. Estimated completion is 2031-06-01.

What conditions does trial NCT05612789 study?

This clinical trial studies the following conditions: Allogeneic Transplantation.

What interventions are being tested in trial NCT05612789?

The interventions under investigation include: Exercise Program (Cohort A Prehab) (BEHAVIORAL), Exercise Program (Cohort B Rehab) (BEHAVIORAL).

Who is sponsoring clinical trial NCT05612789?

This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05612789 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Allogeneic Transplantation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.